炎症体
体内
体外
化学
药物发现
计算生物学
生物化学
生物
受体
遗传学
作者
Chunxiao Sun,Yuqi Jiang,Changlong Li,Simin Sun,Jiaqi Lin,Wenxue Wang,Luning Zhou,Liping Liang,Mudassir Shah,Qian Che,Guojian Zhang,De Wang,Tianjiao Zhu,Dehai Li
标识
DOI:10.1002/anie.202405860
摘要
Numerous clinical disorders have been linked to the etiology of dysregulated NLRP3 (NACHT, LRR, and PYD domain-containing protein 3) inflammasome activation. Despite its potential as a pharmacological target, modulation of NLRP3 activity remains challenging. Only a sparse number of compounds have been reported that can modulate NLRP3 and none of them have been developed into a commercially available drug. In this research, we identified three potent NLRP3 inflammasome inhibitors, gymnoasins A-C (1-3), with unprecedented pentacyclic scaffolds, from an Antarctic fungus Pseudogymnoascus sp. HDN17-895, which represent the first naturally occurring naphthopyrone-macrolide hybrids. Additionally, biomimetic synthesis of gymnoasin A (1) was also achieved validating the chemical structure and affording ample amounts of material for exhaustive bioactivity assessments. Biological assays indicated that 1 could significantly inhibited in vitro NLRP3 inflammasome activation and in vivo pro-inflammatory cytokine IL-1β release, representing a valuable new lead compound for the development of novel therapeutics with the potential to inhibit the NLRP3 inflammasome.
科研通智能强力驱动
Strongly Powered by AbleSci AI